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Abstract: Severe hyperkalemia requires urgent medical attention and correction in order to 
prevent arrhythmic complications. Sodium polystyrene sulfonate (SPS) is a cation exchange resin 
commonly used in the management of hyperkalemia. A recent review raised concerns regarding 
its effectiveness and potential adverse effects. Hypernatremia in adults in the setting of sodium 
polystyrene sulfonate therapy has not been described in the literature. We report the case of a 
woman who developed hypernatremia in the setting of excessive SPS administration and hope 
to increase awareness among clinicians regarding this potential side effect of SPS therapy.
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Background
Hyperkalemia is a medical emergency primarily due to its cardiotoxic effects. In addition 
to cardiac membrane stabilization with intravenous calcium and redistribution of 
cellular potassium with insulin, beta antagonists, or bicarbonate, therapy with a cation 
exchange resin is often used in order to promote net potassium loss in the intestinal 
tract.1,2 A recent review raised concerns regarding its effectiveness and potential adverse 
effects of this agent.3 Two cases of hypernatremia in the setting of sodium polystyrene 
sulfonate (SPS) treatment have been reported in neonates.4 We describe the case of an 
adult female patient who developed hypernatremia during treatment with SPS.
Case report
A 44-year-old female nursing home resident, with normal baseline renal function 
was admitted to the hospital for confusion and lethargy. She had poor oral intake 
for the week prior to admission and recently her narcotic medications have been 
increased for worsening back pain. Her outpatient medications included furosemide, 
spironolactone, and lisinopril. Her medical history was notable for cirrhosis due 
to hepatitis C, hypothyroidism, hypertension, and chronic back pain. Initial evalu-
ation revealed acute renal failure with creatinine of 5.1 mg/dL and hyperkalemia 
(7.1 mmol/L). Her initial serum sodium was normal (140 mEq/L); however, in the 
following hours she developed hyponatremia (128 mEq/L). On physical examination 
she appeared dehydrated and lethargic. Laboratory values on admission and subse-
quently on follow-up are presented in Table 1. Her electrocardiogram revealed sinus 
tachycardia without T-wave changes.
She was treated with intravenous insulin and dextrose, intravenous saline infu-
sion, and SPS (60 g every 6 hours). Her urine output improved, and the patient International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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developed diarrhea over the next hours. A total of 240 g of 
SPS was administered during a 24-hour period, before the 
discontinuation of this order. Her serum sodium started at 
140 Meq/L and then decreased to 128 mEq/L. Twenty-four 
hours after admission, her sodium level was 141 mEq/L, then 
increased over the second hospital day to 151 mEq/L. During 
the first 2 days in the hospital she passed large amounts of 
liquid stool. Given the concerning rate of serum sodium rise, 
an infusion of dextrose water solution was administered and 
sodium levels were closely monitored. Her thyroid and adre-
nal function were adequate. Her serum sodium normalized 
over the next 3 days with replacement of the free water deficit. 
Her renal function and potassium levels returned to normal. 
Her low fractional excretion of sodium and physical signs 
of volume depletion led us to believe that the net free water 
loss due to SPS-induced diarrhea resulted in this patient’s 
hypernatremia rather than a sodium–potassium exchange 
mechanism. The patient had no major long-term neurologic 
complications.
Discussion
SPS is a cation exchange resin used to induce a net potassium 
loss in patients with moderate to severe hyperkalemia. With 
the growing chronic kidney disease and end stage renal disease 
patient population, hyperkalemia is a relatively common 
electrolyte abnormality encountered in clinical practice. SPS 
is commonly used when serum potassium levels are high as 
an adjunct medical treatment measure. Although its safety and 
efficacy are being questioned,4 the mechanism of action of SPS 
is thought to be the net exchange of potassium in the intestinal 
lumen with sodium in order to maintain electrical neutrality. 
Each gram of resin may bind as much as 1 mEq of potassium 
and exchange it for 1–2 mEq of sodium. To facilitate the 
passage of the resin through the gastrointestinal tract, sorbitol 
was added to the resin, resulting in a cathartic effect.2 Compli-
cations of SPS therapy, although rare, include ischemic colitis 
and colonic necrosis,2,4 hypocalcemia,5 volume overload, and 
iatrogenic hypokalemia.
The hypernatremia in our patient is likely due to net 
intestinal water loss, in the setting of profuse osmotic diarrhea 
induced by SPS therapy. It is unclear whether salt loading 
from the cation exchange mechanism played a role in the 
  pathogenesis. Only two cases of combined water loss combined 
with a sodium loading have been reported in the   literature, 
both in low birth neonates.3 In our patient, the relatively rapid 
correction of hyponatremia may also have been contributed to 
by antidiuretic hormone suppression in the setting of the res-
toration of intravascular volume. Although the   relative change 
Table 1 Results of laboratory testsa
Variables Normal  
values
Day 0 (Hours after admission) Day 1 Day 2 Day 3
1 hour  
(SPS given)
6 hours  
(SPS given)
12 hours  
(SPS given twice)
16.5 hours
sodium  
(mmol/L)
135–145 140 128 141 149 151 143 140
Potassium  
(mmol/L) 
3.8–4.8 7.1 7.5 8.7 6.1 5.2 4.2 3.7
Chloride  
(mmol/L)
100–108 95 98 104 110 108 109 105
Carbon dioxide  
(mmol/L)
23.0–31.9 17 18 18 22 26 24 27
Urea Nitrogen  
(mg/dL)
8–25 69 72 71 70 65 36 31
Creatinine  
(mg/dL)
0.6–1.5 5.1 4.7 4.1 3.5 2.0 0.9 0.9
Glucose  
(mg/dL)
70–110 74 115 96 102 116 102 131
Calcium  
(mg/dL)
8.5–10.5 7.4 7.6 7.9 7.5 7.9 8.6 8.9
Magnessium  
(mg/dL)
1.4–2.8 – – 2.2 – 2.0 – –
Osmolality  
(mOsm/kg)
278–305 – – – 303 – – –
Notes: aTo convert the values for urea nitrogen to millimoles per liter, multiply by 0.357. To convert the values for creatinine to micromoles per liter, multiply by 88.4. 
To convert the values for glucose to millimoles per liter, multiply by 0.5551. To convert the values for calcium to millimoles per liter, multiply by 0.250. To convert the values 
for magnesium to millimoles per liter, multiply by 0.25. Trend of rising sodium after giving sodium polystyrene sulfonate (sPs) treatment for hyperkalemia. Patient received a 
total of four doses of 60 g sPs in less than 24 hours, thereby raising the sodium level up to 151 mmol/L, which was normalized by free water hydration.International Journal of Nephrology and Renovascular Disease
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of serum sodium was significant, the patient’s serum sodium 
returned to the initial normal value within the first hospital 
day and then increased by 9 mEq/L in the next 24 hours. This 
change was slightly higher than the currently recommended 
rates of change,6 but there were no adverse clinical conse-
quences observed in long-term follow-up.
This case illustrates a potential side effect of excessive 
administration of SPS in hospitalized adults. As a quality 
improvement measure, our institutional pharmacy no longer 
accepts standing orders for SPS. We hope to raise aware-
ness of this potential side effect of SPS among the medical 
community.
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